How to Buy Humacyte Stock
Humacyte Inc
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
Humacyte stock last closed at $0.82, down 3.3% from the previous day, and has decreased 42.66% in one year. It has underperformed other stocks in the Biotechnology industry by 0.32 percentage points. Humacyte stock is currently +49.91% from its 52-week low of $0.55, and -72.01% from its 52-week high of $2.93.
There are currently 222.02M shares of HUMA outstanding. The market cap of HUMA is $182.06M. In the past 24 hours, 3.45M HUMA shares were traded.
How to Buy Humacyte Stock
Not sure how to invest in Humacyte stock? Here's how.
- Decide where to buy Humacyte stock: You need to pick a stock brokerage, but don't worry - we've tested dozens of online stock brokerages and apps to help you determine where to buy Humacyte stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit funds into your investment account: Pick your method of payment and add your information.
- Research Humacyte stock: The Humacyte ticker symbol is HUMA. Is Humacyte stock a good investment? Should you buy shares of HUMA? How do HUMA's underlying business fundamentals look? Do top analysts think Humacyte is a good buy? Why has HUMA's stock price moved recently? (Hint: Our stock market research website can help you figure out if HUMA is a good stock to buy).
- Make your HUMA trade: Decide if you will purchase HUMA shares at the current market price or use a limit order to purchase HUMA shares at a given price.
- Get key alerts regarding your investment in HUMA: Create a watchlist to keep tabs on your new investment in Humacyte stock.
Step 1: Decide where to buy Humacyte stock
You need a brokerage account in order to access the NASDAQ market and buy HUMA shares.
Our recommended brokerage: eToro
We believe that eToro is the best online stock brokerage. eToro gives you:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global financial markets: From Technology to Industrials, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro offers a community of more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've chosen the best brokerage, you'll need to fill out some personal details so you can buy HUMA today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to create your new trading account.
- Submit your data by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have created your account on the highest rated app to buy and sell stocks, your next step is to transfer the money for your investment:
Watch this video walkthrough to see the process of transferring money into your new investment account.
Step 4: Research Humacyte stock
Once you have decided on the best place to buy Humacyte stock, it's important to analyze their stock prior to buying, so you actually understand the risk and opportunity.
Humacyte Metrics
Humacyte Due Diligence Score
WallStreetZen was designed to help everyday investors perform better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on HUMA's stock page.
How is HUMA stock valued?
Investors use many financial metrics, analyses, models, and charts to gauge HUMA's fair value.
Using relative valuations ratios:
- HUMA could be overvalued based on its P/B ratio of 58.56x, relative to Biotechnology industry P/B ratio of 4.76x
You can do additional valuation research on HUMA's stock here.
A quick look at HUMA Financials
Signs that HUMA is financially healthy:
- Total HUMA debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the HUMA balance sheet.
Signs that HUMA is not financially healthy:
- HUMA has $50.71M in cash and short term investments. This is not sufficient to cover its annual cash burn of $105.93M.
- HUMA has cash burn of 105926000. It does not have sufficient cash and short-term investments to cover this.
- HUMA profit margin has gone down from N/A to -2,003.6% in the past year.
- There are more long-term liabilities than short-term assets on the HUMA balance sheet.
- HUMA has a relatively high debt to equity ratio of 36.43.
Is HUMA stock a Buy, Hold, or Sell, according to analysts?
Out of 6 Equities analysts who give forecasts on HUMA, the consensus analyst rating on Humacyte is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they financial advice.
Latest HUMA Analyst Upgrades/Downgrades
Joshua Jennings, a top 24% analyst from TD Cowen maintains HUMA with a strong buy rating and lowers their HUMA price target from $3.50 to $1.00, on Mar 30, 2026.
You can dive deeper into what analysts are projecting on the Humacyte stock forecast page.
HUMA Technicals
HUMA Revenue
Last year, HUMA revenue was $2.04M. Over the last five year, HUMA's revenue has grown by 6.45% per year. This was slower than the Biotechnology industry average of 27.44%.
Find out more about HUMA's earnings and revenue performance here.
Are HUMA insiders buying or selling the stock?
Over the last 12 months, executives and large shareholders at HUMA have sold more shares than they have bought.
Brady W. Dougan, Director of HUMA, was the latest HUMA insider to sell. They sold $934,862.30 worth of HUMA stock on Aug 20, 2025.
Dig into more about who owns HUMA stock here.
Can I rely on HUMA as an income stream?
No, Humacyte doesn't provide an income stream by paying out dividends.
What others are saying about HUMA
One of the reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Make your HUMA trade
There are two main order types:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are usually fine. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at a particular dollar amount, use a limit order.
Press the Open button and eToro will execute your order.
If you need additional help buying stocks on eToro, click the how to video below:
Step 6: Get key alerts regarding your investment in HUMA
Now that you own some HUMA shares, you'll want to stay up-to-date on your company.
Make a watchlist to get alerted to the latest events about your HUMA stock.
HUMA Feed
How to Buy Stock in Humacyte
To reiterate, here are the 6 steps to buy Humacyte stock:
- Decide where to buy Humacyte stock
- Open a brokerage account
- Deposit funds into your investment account
- Research Humacyte stock
- Make your HUMA trade
- Get key alerts regarding your investment in HUMA
If you are looking for a online brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to watch your new investment in Humacyte, add HUMA to your watchlist below.
More Content You Might Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.